Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00550
|
|||||
| Drug Name |
Bromocriptine
|
|||||
| Synonyms |
(5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione; (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman; (6aR,9R)-5-Bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide; 2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotamin-3',6',18-trione; 2-Bromo-alpha-ergocryptine; 2-Bromo-alpha-ergokryptin; 2-Bromo-alpha-ergokryptine; 2-Bromoergocryptine Methanesulfonate; 2-Bromoergokryptine; Alti-Bromocriptine; Apo-Bromocriptine; Bagren; Bromergocryptine; Bromocriptin; Bromocriptina; Bromocriptina [INN-Spanish]; Bromocriptine (USAN/INN); Bromocriptine [BAN]; Bromocriptine [USAN:BAN:INN]; Bromocriptine methanesulfonate; Bromocriptinum; Bromocriptinum [INN-Latin]; Bromocryptin; Bromocryptine; Bromoergocriptine; Bromoergocryptine; CB-154; Ergocryptine, 2-bromo-(8CI); Ergoset; Parlodel; Parlodel (TN); Parlodel Snaptabs
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Type 2 diabetes [ICD11: 5A11] | Approved | [1] | |||
| Therapeutic Class |
Antiparkinson Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C32H40BrN5O5
|
|||||
| Canonical SMILES |
CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O
|
|||||
| InChI |
InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1
|
|||||
| InChIKey |
OZVBMTJYIDMWIL-AYFBDAFISA-N
|
|||||
| CAS Number |
CAS 25614-03-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 654.6 | Topological Polar Surface Area | 118 | ||
| Heavy Atom Count | 43 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
3.8
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103170197
, 103936294
, 104309997
, 11405760
, 11466149
, 11467269
, 11485837
, 117390441
, 124749509
, 124886913
, 126625420
, 126656565
, 127298886
, 127298887
, 127298888
, 127298889
, 127298890
, 127298891
, 127298892
, 127298893
, 127298894
, 127298895
, 127298896
, 127298897
, 127298898
, 14765834
, 14765835
, 17397319
, 24262982
, 34673282
, 46505504
, 47217056
, 47440541
, 47589227
, 47589228
, 47885652
, 48415647
, 49658626
, 49965589
, 50872033
, 53789332
, 57311062
, 605475
, 7978821
, 8171939
, 85788755
, 90340796
, 9074
, 92712670
, 93166622
|
|||||
| ChEBI ID |
ChEBI:3181
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Bromocriptine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.